Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL SA vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics at higher concentrations.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
55-60% bound, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.45 L/kg (0.3-0.7 L/kg). Reflects distribution into total body water, with lower Vd in obese patients when adjusted for ideal body weight.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 100% for choline theophyllinate (Choledyl) as it is completely absorbed; the sustained-action formulation (Choledyl SA) has equivalent bioavailability to immediate-release.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 50-80 m L/min: 50% of usual dose; GFR <50 m L/min: avoid use due to accumulation of choline and theophylline.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: 50% of usual dose; Child-Pugh B: 25% of usual dose; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Not recommended for use in children under 12 years due to lack of safety data.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Initiate at 400 mg every 12 hours; titrate slowly with monitoring of serum theophylline levels due to reduced clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Theophylline has narrow therapeutic index; serum levels must be monitored to avoid toxicity (toxicity risk increases above 20 mcg/m L).,Concomitant use with other xanthines may potentiate toxicity.,Use with caution in patients with cardiovascular disease (e.g., arrhythmias), seizure disorders, hepatic impairment, or peptic ulcer disease.,Drug interactions: CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) increase theophylline levels; CYP1A2 inducers (e.g., phenytoin, rifampin) decrease levels.,Risk of hypokalemia and hypophosphatemia with high doses or prolonged use.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation.,Acute myocardial infarction with bradycardia or tachyarrhythmias.,Active seizure disorder not controlled with anticonvulsant therapy.
Hypersensitivity to theophylline or any component of the formulation.
Avoid high-fat meals that may alter absorption. Caffeine (coffee, tea, cola, chocolate) potentiates adverse effects. Charcoal-broiled foods can increase theophylline metabolism.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unknown; use only if benefit outweighs risk. Second/third trimester: possible fetal tachycardia and irritability; avoid near term due to potential neonatal apnea, jitteriness, and withdrawal symptoms.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Infant may receive 1-10% of maternal dose. Monitor infant for irritability, insomnia, and tachycardia. Use caution; benefit should outweigh risk. Alternative agents may be preferred.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy may reduce theophylline clearance (especially third trimester) due to decreased hepatic metabolism and increased volume of distribution. Dose reduction may be needed; monitor levels and adjust to maintain therapeutic range. Postpartum clearance increases rapidly; adjust dose downward after delivery to avoid toxicity.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Choledyl SA (oxtriphylline) is a sustained-release theophylline salt. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active peptic ulcer disease and seizure disorders. Cigarette smoking induces metabolism, requiring dose adjustments. Use with caution in patients with hepatic impairment, cardiac disease, or hypothyroidism.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid excessive consumption of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Notify your doctor if you experience nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop taking abruptly; dose tapering may be needed.,Inform your doctor if you smoke or stop smoking, as dose adjustments may be required.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL SA vs AEROLATE JR, answered by our medical review team.
CHOLEDYL SA is a Bronchodilator that works by Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL SA and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL SA is: 400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL SA and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL SA is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unkn. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.